At present, clinical diagnosis to select patients with ALK fusion–positive NSCLC is predominantly performed by IHC test, while NGS screening might have the potential to test for multiple gene alterations in a quick single analysis. This evidence concerns the gene ALK and non-small cell lung carcinoma.